ATS — ATS Corporation

ATS Corporation Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $744 million, up 3.2% year-over-year.
• Adjusted Earnings from Operations: $76.8 million, a 3.4% increase from Q4 last year.
• Gross Margin: 29.4%, a 36 basis point increase year-over-year.
• Order Bookings: $704 million, down 18.4% compared to Q4 last year, reflecting prior large project awards.
• Order Backlog: Approximately $2 billion, with Life Sciences comprising $1.1 billion (55% of total).
• Adjusted EPS: $0.36 for the quarter.
• Free Cash Flow: $149.5 million, marking six consecutive quarters of positive growth.
• Net Debt to Adjusted EBITDA Ratio: 2.8x, showing continued improvement.

2. Strategic Updates and Business Highlights

• ATS is consolidating its transportation operations, moving away from large-scale automotive projects to focus on specialized applications.
• The company is enhancing its digital twin offerings and integrating aftermarket services into operating units to improve margins and revenue predictability.
• Strong performance in Life Sciences, particularly in the radiopharma sector, with a broader funnel of opportunities beyond single program types.
• Energy sector backlog increased by approximately 40% year-over-year, driven by nuclear refurbishment and new build programs.
• ATS is focused on capital efficiency and margin expansion, with plans for targeted investments in growth areas like nuclear and radiopharma.

3. Forward Guidance and Outlook

• Q1 2027 Revenue Guidance: Expected to be in the range of $700 million to $740 million.
• Fiscal 2027 Outlook: Modest revenue growth anticipated, with the transportation segment expected to decline.
• Margin Improvement: Expected adjusted earnings from operations margins to improve by 50 to 75 basis points over fiscal 2026, supported by reorganization actions and operational discipline.
• Long-term margin target remains at 15%.

4. Bad News, Challenges, or Points of Concern

• Declining Order Bookings: The 18.4% drop in order bookings raises concerns about future revenue growth, particularly in the consumer products segment.
• Transportation Segment: The decision to exit large-scale automotive work may lead to a revenue decline of approximately $50 million.
• Market Volatility: The company noted potential lumpiness in revenue due to timing of large orders and market dynamics, particularly in Life Sciences.
• Geopolitical and Trade Uncertainty: Ongoing macroeconomic challenges could impact future performance, although current tariffs have not materially affected operations.

5. Notable Q&A Insights

• Life Sciences Backlog: Management remains optimistic about growth in Life Sciences, despite some moderation in GLP-1 auto-injector orders. The focus will be on diversifying the backlog with radiopharma and other applications.
• M&A Activity: ATS plans to pursue M&A opportunities independently of the ongoing restructuring, viewing both as capital deployment exercises.
• Working Capital Management: Strong performance in working capital efficiency is a priority, with a target of maintaining levels below 15%.
• Recurring Revenues: Approximately one-third of ATS's business is recurring, with initiatives underway to increase this percentage, which tends to be margin-accretive.

Overall, ATS Corporation's Q4 2026 results reflect solid execution and strategic focus, but challenges in order bookings and market volatility present potential headwinds for the upcoming fiscal year.